PEABODY, Mass., Sept. 24, 2020 -- Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat... read more

Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more

Peabody, MA -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more

Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was... read more

Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research... read more

Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the... read more

Privo Technologies expands to a new 3000 square foot facility just outside of Boston, MA. Located at 200 Corporate... read more

Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston... read more

Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce... read more

Privo Technologies, Inc.  attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this... read more